Saturday 17 October 2026 Export CSCIF’s income statement to Excel — free account

COSCIENS Biopharma Inc.

COSCIENS Biopharma Inc.’s revenue for fiscal 2025 (year ended December 2025) was $7.5 million, down 21.8% from fiscal 2024. In the quarter to June 2026, revenue grew 30.0%, EPS grew 92.6% and free cash flow grew 113.3%, each against the same quarter a year earlier.

6.49 0.24 +3.84%

Follow CSCIF

Alert me

Market cap: $8.6M
P/E: 1.0×
Fwd P/E: —
Dividend yield: —
F-score: 3/9
Altman Z: −2.08
Beneish M: −2.95
Dividend safety: n/a

Overview Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 0.00%

Capital & Financial Ratios $m

Market Cap 8.57

Revenue 8.73

Net Income 6.55

Free Cash Flow (3.52)

Net Debt (5.28)

Current Ratio 4.33

Debt/Equity 0.00

P/E ratio 1.03

Fwd P/E —

P/S ratio 0.78

P/B ratio 0.46

Past 5Y EPS Growth —

This Y EPS Growth —

Next Y EPS Growth —

Next Y revenue growth —

Next 5Y EPS Growth —

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 37.67%

10-year low 10-year high

P/B against its own 10 years 55.07%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	7	16	7	5
Receivables	0	2	1	2
Inventory	4	3	1	1
Other	—	—	0	—
	11	24	12	10

	2023	2024	2025	Q'26
Payables	1	5	2	1
ST’ Debt	—	—	—	—
Other	0	2	1	1
	1	7	4	2

Compound Annual Growth %

	10y	5y	3y
Sales	29.97%	15.47%	9.96%
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	(15.86%)	(21.89%)	(52.47%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	2	3	—	—	—
’25	1	2	1	2	7
’24	2	2	2	3	10
’23	2	1	2	2	7
’22	2	0	2	2	6
’21	2	2	1	1	5
’20	1	0	0	2	4

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(2)	1	—	—	—
’25	(2)	(4)	(1)	(1)	(8)
’24	(2)	(1)	(8)	(3)	(15)
’23	(4)	2	0	(1)	(3)
’22	(1)	(5)	(4)	(3)	(14)
’21	(1)	(4)	(1)	(2)	(9)
’20	(2)	(2)	(2)	3	(4)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(2)	1	—	—	—
’25	(2)	(4)	(1)	(1)	(9)
’24	(3)	(2)	(8)	(3)	(16)
’23	(4)	2	0	(1)	(3)
’22	(1)	(5)	(4)	(3)	(14)
’21	(2)	(4)	(1)	(3)	(9)
’20	(2)	(2)	(2)	3	(4)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	8.70	(0.19)	—	—	—
’25	(3.48)	(2.55)	(1.71)	(2.07)	(9.81)
’24	(2.27)	(1.92)	(5.55)	(6.45)	(17.79)
’23	(10.56)	(1.40)	(1.26)	(13.92)	(5.66)
’22	(6.00)	(10.44)	(8.40)	(30.72)	(56.17)
’21	(4.58)	(6.00)	(4.78)	(6.00)	(21.00)
’20	12.00	(45.00)	(6.00)	(6.00)	(36.00)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	260.00	78.00	112.00	76.00	29.00	35.00	11.56	5.44	2.50	1.70	Analyst estimates 2026–2028 Powerpack
	High	559.00	375.00	392.00	557.00	154.00	362.00	44.00	15.76	11.10	4.61
People
People	Employees	47	34	22	11	8	17	21	21	40	28
	Revenue/emp, $m	0.02	0.03	1.22	0.05	0.46	0.31	0.27	0.34	0.24	0.27
Income, $m
Income, $m	Revenue	1	1	27	1	4	5	6	7	10	7
	Gross margin, %	100.00	100.00	92.17	22.93	36.56	98.29	97.22	41.13	49.33	35.30
	EBT	(25)	(20)	10	(6)	(5)	(8)	(23)	(4)	(15)	(10)
	EBT margin, %	(2,739.74)	(2,196.64)	35.86	(1,171.05)	(129.33)	(161.16)	(402.96)	(61.18)	(158.81)	(138.01)
	Net income	(25)	(17)	4	(6)	(5)	(8)	(23)	(3)	(15)	(10)
	Depreciation	0	0	(1)	0	1	(2)	(2)	1	1	1
Per share, $
Per share, $	Revenue	26.41	18.50	490.53	9.13	26.68	13.73	13.94	11.60	11.15	7.11
	Earnings	(723.07)	(336.03)	75.01	(105.01)	(36.00)	(21.00)	(56.17)	(5.66)	(17.79)	(9.81)
	Cash flow	(840.87)	(459.18)	124.54	(183.96)	(30.16)	(22.40)	(33.81)	(4.19)	(16.94)	(8.03)
	Capex	(1.86)	3.15	0.27	0.00	0.04	(1.67)	(0.03)	(0.28)	(1.35)	(0.44)
	Free cash flow	(842.72)	(456.03)	124.82	(183.96)	(30.12)	(24.07)	(33.84)	(4.48)	(18.29)	(8.47)
	Book value	180.06	(55.77)	34.80	(42.25)	96.50	138.34	88.42	34.17	15.30	3.64
	Shares, m	0	0	0	0	0	0	0	1	1	1
Valuation, ×
Valuation, ×	P/E	0.00	0.00	3.77	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	13.25	12.81	0.60	9.97	1.61	2.62	0.92	0.65	0.25	0.29
	P/B	1.94	0.00	8.45	0.00	0.45	0.26	0.15	0.22	0.18	0.57
	EV/Sales	(10.89)	4.38	0.06	(4.76)	(5.03)	(9.79)	(8.05)	(0.29)	(1.46)	(0.68)
	EV/FCF	0.34	(0.18)	0.11	0.24	4.48	5.59	3.17	0.71	0.92	0.60
Cash, $m
Cash, $m	Operating cash flow	(29)	(23)	7	(11)	(4)	(9)	(14)	(3)	(15)	(8)
	Capex	0	0	0	—	0	(1)	0	0	(1)	0
	Free cash flow	(29)	(23)	7	(11)	(4)	(9)	(14)	(3)	(16)	(9)
Balance, $m
Balance, $m	Working capital	19	4	11	5	23	63	48	10	17	8
	Total debt	—	—	—	—	—	—	—	—	—	—
	Net debt	(22)	(8)	(15)	(8)	(24)	(65)	(51)	(7)	(16)	(7)
	Shareholders’ equity	6	(3)	2	(2)	13	53	36	21	13	4
Returns, %
Returns, %	ROA	(60.03)	(62.38)	17.74	(26.86)	(17.96)	(14.29)	(33.39)	(8.74)	(52.06)	(36.66)
	ROIC	0.00	0.00	0.00	0.00	0.00	0.00	0.00	(20.15)	0.00	0.00
	ROE	(179.39)	(979.64)	(955.94)	2,173.38	(95.24)	(25.28)	(51.21)	(12.27)	(89.54)	(121.84)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
MTVA MetaVia Inc.	$9.0M	— (loss-making)	—	—	n/m	−22.42% (below 0%: shrinking)	—	0.00%	Compare
JAGX Jaguar Animal Health, Inc.	$8.9M	0.0×	— (loss-making)	−58.88% (below 0%: shrinking)	n/m	+13.83% (above 0%: growing)	15.84%	(620.16%)	Compare
NKGN NKGen Biotech, Inc.	$8.8M	— (loss-making)	—	—	n/m	+28.68% (above 0%: growing)	100.00%	0.00%	Compare
CSCIF COSCIENS Biopharma Inc.	$8.6M	1.0×	—	+30.04% (above 0%: growing)	n/m	+113.30% (above 0%: growing)	55.27%	13.43%
IMRN IMMURON	$8.3M	— (loss-making)	—	+757.00% (above 0%: growing)	+12.00% (above 0%: growing)	+42.55% (above 0%: growing)	72.16%	0.00%	Compare
ADIL Adial Pharmaceuticals, Inc.	$8.3M	— (loss-making)	—	—	n/m	−263.66% (below 0%: shrinking)	0.00%	0.00%	Compare
BOLT Bolt Biotherapeutics, Inc.	$8.2M	— (loss-making)	— (loss-making)	−99.72% (below 0%: shrinking)	n/m	+38.87% (above 0%: growing)	100.00%	(167,480.00%)	Compare
SNTI Senti Biosciences, Inc.	$8.1M	— (loss-making)	— (loss-making)	−98.68% (below 0%: shrinking)	n/m	−7.48% (below 0%: shrinking)	100.00%	(85,229.41%)	Compare
QNRX Quoin Pharmaceuticals, Ltd. Sponsored ADR	$8.1M	— (loss-making)	—	—	n/m	−510.28% (below 0%: shrinking)	0.00%	0.00%	Compare
Median of peers	$8.3M	—	—	−78.78%	—	+3.18%	72.16%	0.00%

All 614 Biotechnology stocks →

COSCIENS Biopharma Inc. (CSCIF) key facts

Concern: COSCIENS Biopharma Inc.’s revenue for fiscal 2025 (year ended December 2025) was $7.5 million, down 21.8% from fiscal 2024.
COSCIENS Biopharma Inc. (CSCIF) is a Biotechnology company in the Healthcare sector.
As of October 16, 2026, CSCIF traded at $6.49, a market capitalization of $8.6 million.
Return on equity was −121.8% and debt-to-equity 0.00.
Its Piotroski F-score is 3 out of 9 and its Altman Z-score is −2.08 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.